TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 79031
Drug: Oral linoleic-acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral linoleic-acid supplementation for 10 months
Study: 30934797
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g PolyGlycopleX softgel capsules (PGXS)
Study: 30934797
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g rice flour (RF)
Study: 26070406
Drug: Paritaprevir plus
Normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paritaprevir plus ritonavir (200/100 mg), ombitasvir (25 mg), and dasabuvir (400 mg)
Study: 21806904
Drug: No parental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No parental presence during dental treatment
Study: 16505424
Drug: Shorter time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter time between the first day of chemotherapy and the last day of chest radiation (SER)
Study: 17145253
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg, sustained-release)
Study: 8905472
Drug: Clonidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (300 micrograms po at 0 min) before and after testosterone replacement (250 mg i.m. every 21 days)
Study: 6344041
Drug: Aspirin 1300
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 1300 mg
Study: 18416823
Drug: RAISINS +
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RAISINS + WALK (combination of both interventions)
Study: 9487836
Drug: 20% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sodium bicarbonate dentifrice, 1.5% hydrogen peroxide solution, mouth moisturizer
Study: 9487836
Drug: Crest dentifrice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crest dentifrice, Toothette Plus with hydrogen peroxide solution, mouth moisturizer
Study: 9487836
Drug: Crest dentifrice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crest dentifrice, Toothette Plus with control solution, no mouth moisturizer
Study: 9487836
Drug: Crest dentifrice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crest dentifrice, Toothette without baking soda, control solution, no mouth moisturizer
Study: 12748132
Drug: Single subacromial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subacromial injection of methylprednisolone with bupivicaine (group S, n=54)
Study: 11076414
Drug: Pumpan (homeopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpan (homeopathic compound)
Study: 2071888
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 10 mg doses of vinpocetine
Study: 2071888
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 20 mg doses of vinpocetine
Study: 6827767
Drug: Night urinary
Normalized name: URINARY NIGHT DRAINAGE BOTTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night urinary sodium excretion estimated by quantitative chloride titrator strips
Study: 31427345
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan injection
Study: 27821083
Drug: Selective Internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Internal Radiation Therapy (SIRT) using yttrium‐90 resin microspheres (SIR‐Spheres®)
Study: 27821083
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral Sorafenib (Nexavar®) at a dose of 400 mg twice daily
Study: 27821083
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral Sorafenib (Nexavar®)
Study: 18591574
Drug: Aripiprazole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (mean dose approximately 9 mg/day at endpoint; range = 0.7‐15.0 mg)
Study: 8771941
Drug: Mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 500 mg (original manufacturer)
Study: 8771941
Drug: Mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 500 mg (locally produced)
Study: 24924603
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium hydrogel patch (LX‐P)
Study: 24924603
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium tablet (LX‐T)
Study: 20628238
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment for 1 year
Study: 16151760
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg IV infused eletriptan
Study: 7654506
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg s.c. every other day for 4 weeks post-splenectomy)
Study: 7654506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no thymopentin treatment)
Study: 2199642
Drug: Dexamethasone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1.0 mg/kg/day for 3 days, then progressively decreased for 12 days)
Study: 342624
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccines containing 200 or 400 chicken cell‐agglutinating units of both A/New Jersey/76 and A/Victoria/75 antigens
Study: 342624
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of vaccines
Study: 342624
Drug: Later revaccinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later revaccinations due to low titers of A/Victoria antibody
Study: 6752800
Drug: Photocoagulation therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocoagulation therapies
Study: 29096225
Drug: Mat-based Pilates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mat-based Pilates training (60-min sessions, twice a week for 16 weeks)
Study: 18065407
Drug: high CHOEP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high CHOEP (cyclophosphamide 1400 mg/m2, doxorubicin 65 mg/m2, vincristine 2 mg, etoposide 175 mg/m2 x3, prednisone 100 mg x5)
Study: 6661892
Drug: Flurbiprofen 250
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 250 mg/day
Study: 6661892
Drug: Ketoprofen 150
Normalized name: ketoprofen 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 150 mg/day
Study: 29749805
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion (NAH w|lac)
Study: 29749805
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (NAH w|placebo)
Study: 29749805
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion (IAH w|lac)
Study: 27569177
Drug: Dance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance therapy (8-week, 3-times-per-week programme)
Study: 27569177
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (usual activities and medication)
Study: 22704138
Drug: Vigabatrin 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin 3000 mg/day
Study: 12030732
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg t.i.d. for 12 weeks
Study: 10492107
Drug: Oral 17beta‐oestradiol/oestriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17beta‐oestradiol/oestriol (Trisequens) with norethisterone acetate
Study: 10492107
Drug: Transdermal 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐oestradiol (Estrapak) with norethisterone acetate
Study: 8684407
Drug: Terazosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (10 mg daily)
Study: 8684407
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terazosin and finasteride
Study: 2018208
Drug: 2.0 mg/kg/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg/20 min
Study: 2018208
Drug: 2.5 mg/kg/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg/20 min
Study: 2018208
Drug: 2.0 mg/kg/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg/10 min
Study: 6786069
Drug: verapamil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (400 +/- 80 mg/day)
Study: 6786069
Drug: nifedipine (82
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (82 +/- 31 mg/day)
Study: 27777129
Drug: 100mg aspirin
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin
Study: 27777129
Drug: 300mg aspirin
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg aspirin
Study: 27777129
Drug: 100mg aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin, 300mg aspirin, matched placebo
Study: 22277663
Drug: Palonosetron (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.075 mg bolus)
Study: 22277663
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg bolus + 16 mg in PCA)
Study: 18496393
Drug: Rectoanal inhibitory
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectoanal inhibitory reflex (RAIR) assessment with balloon distention (10 to 50 mL) in constipation patients
Study: 12180224
Drug: Antibacterial prophylaxis
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial prophylaxis (1 g i.v. injection of cephradine at induction of anaesthesia) (Group C)
Study: 2015177
Drug: Yohimbine (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (22 mg)
Study: 2015177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine and yohimbine
Study: 31277532
Drug: Acupotomy-injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupotomy-injection technique with targeted three-point
Study: 31277532
Drug: Small needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small needle knife therapy
Study: 22152089
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol (MF/F) 200/10 μg via metered-dose inhaler (MDI) BID
Study: 22152089
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/S) 250/50 μg via dry powder inhaler (DPI) BID
Study: 19776771
Drug: Anti-aggregation with
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-aggregation with dipyridamole and aspirin
Study: 15448954
Drug: Glucocorticoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid therapy (GCC)
Study: 8591949
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin
Study: 8591949
Drug: Chloroquine monotherapy
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine monotherapy (45 mg/kg over 3 days)
Study: 2474057
Drug: LNH-84 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNH-84 regimen (ACVB) comprising doxorubicin 75 mg/m2, cyclophosphamide 1200 mg/m2, vindesine 2 mg/m2 x 2, bleomycin 10 mg x 2, prednisolone 60 mg/m2 x 5, followed by high-dose methotrexate, ifosfamide, etoposide, asparaginase, and cytarabine, with late intensification using AraCVmB.
Study: 31282921
Drug: Adjunctive corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroids (prednisolone acetate, 50 mg/d for 7 days) and other bundled interventions
Study: 31282921
Drug: Adjunctive corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroids (intervention group)
Study: 23286834
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of HMB-FA
Study: 1505537
Drug: 4D taper
Normalized name: CAPER BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4D taper (4 days; n = 7)
Study: 1505537
Drug: 8D taper
Normalized name: CAPER BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8D taper (8 days; n = 6)
Study: 1505537
Drug: NOTAPER (non-taper,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOTAPER (non-taper, continued training; n = 6)
Study: 6833021
Drug: Colestipol hydrochloride,
Normalized name: Colestipol Hydrochloride, Micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol hydrochloride, 5 grams qid during therapy
Study: 6833021
Drug: Diphenoxylate hydrochloride
Normalized name: Diphenoxylate Hydrochloride
DrugBank: Diphenoxylate (DB01081)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenoxylate hydrochloride and atropine sulfate, 2.5‐20 mg per day (control) if diarrhea occurred
Study: 24215716
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of recombinant human follicle-stimulating hormone (rhFSH) 300 IU on alternate days for ≥4 months
Study: 17822466
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention using vacuum erection device (VED) starting 1 month after RP, daily for 10 min/day for 5 months.
Study: 12035874
Drug: Long-acting calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting calcium channel blockers (CCBs) such as nifedipine GITS, nitrendipine, and diltiazem
Study: 9697672
Drug: Synthetic urodilatin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic urodilatin (URO) infusion at a low dose of 20 ng x kg(‐1) x min(‐1) for 60 minutes
Study: 10586205
Drug: rHuEpo +
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo + G‐CSF (1 microg/kg) three times a week for 8 weeks (added if PR or NR after rHuEpo)
Study: 10586205
Drug: rHuEpo administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rHuEpo administration
Study: 2518952
Drug: Fragmented virus
Normalized name: palmitoyl fragment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmented virus vaccine
Study: 750603
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (2 g)
Study: 25201903
Drug: LigaSure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LigaSure group (Subgroup g: 3 bars-power levels/1 frequency application)
Study: 16963041
Drug: Fasting glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose, fasting insulin, body mass index, and free T in patients with PCOS
Study: 27048405
Drug: PCT-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided therapy
Study: 23702257
Drug: 9.6% carbohydrate‐caffeine‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.6% carbohydrate‐caffeine‐electrolyte solution with carbohydrate‐electrolyte gels (H‐CHO)
Study: 23702257
Drug: 5.6% carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6% carbohydrate‐electrolyte solution with electrolyte gels (CHO)
Study: 23702257
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution and electrolyte gels (PL)
Study: 22184384
Drug: XP (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Study: 22184384
Drug: XP/XRT/XP (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP/XRT/XP (two cycles of XP followed by 45-Gy XRT with capecitabine 1,650 mg/m2 per day for 5 weeks and two cycles of XP)
Study: 19883407
Drug: Scheduled maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled maintenance treatment with infliximab (5 mg/kg)
Study: 18762502
Drug: Recurrent antichlamydial
Normalized name: Acacia decurrens extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recurrent antichlamydial treatments
Study: 8749726
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg, p.o.)
Study: 8749726
Drug: Amantadine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (300 mg, p.o.)
Study: 8749726
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg, p.o.)
Study: 2049233
Drug: Nifedipine, sparteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, sparteine and phenytoin administered as a 'cocktail'
Study: 2049233
Drug: Single substrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single substrate administration of nifedipine, sparteine and phenytoin
Study: 28337660
Drug: Perioperative ECF
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative ECF chemotherapy alone
Study: 28337660
Drug: Perioperative ECF
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative ECF chemotherapy with preoperative chemoradiation
Study: 15523532
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during acute hemiplegia (Group A)
Study: 15523532
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during chronic hemiplegia (Group B)
Study: 7710234
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous fentanyl
Study: 2901267
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 40 mg daily for 3 weeks to 56 months)
Study: 2901267
Drug: Terazosin in
Normalized name: Product containing terazosin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin in combination with other antihypertensive agents
Study: 26922379
Drug: Bacillus coagulans
Normalized name: Bacillus coagulans
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus coagulans MTCC 5856 tablet containing 2 × 10(9) cfu/day for 90 days
Study: 25693859
Drug: LCZ696 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 100 mg (with optional titration to 200 and 400 mg)
Study: 23617229
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% ophthalmic solution applied daily for 9 months
Study: 17601603
Drug: GnRH‐a/chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a/chemotherapy
Study: 8860064
Drug: Nisoldipine 20
Normalized name: nisoldipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 20 mg twice daily
Study: 1298143
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg Bezafibrate retard
Study: 1298143
Drug: 20 to
Normalized name: Vite20 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 to 80 mg Lovastatin
Study: 31239111
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg per day) for 3 months
Study: 31239111
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg per day) for 6 months
Study: 15094269
Drug: Nevirapine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (400 mg) and efavirenz (800 mg) once daily
Study: 15094269
Drug: Nevirapine once
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine once daily
Study: 15094269
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nevirapine and efavirenz
Study: 7909285
Drug: Salmeterol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (all doses)
Study: 3281702
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (Protocol D)
Study: 3281702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD)
Study: 31028669
Drug: Other second-generation
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other second-generation BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib)
Study: 31028669
Drug: Reversible BTK
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversible BTK inhibitors (vecabrutinib, LOXO-305)
Study: 31028669
Drug: Non-selective reversible
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective reversible BTK inhibitors (ARQ-531)
Study: 21531174
Drug: Gatifloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (10 mg/kg once a day for 7 days)
Study: 21531174
Drug: Chloramphenicol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (75 mg/kg per day in four divided doses for 14 days)
Study: 17136556
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (e.g., natalizumab)
Study: 9342766
Drug: High-dose hypericum
Normalized name: Hypericum oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hypericum extract
Study: 3513716
Drug: Desmopressin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (20 micrograms intranasal nightly for three months)